Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...

Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...

Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Recent health news includes a promising AstraZeneca pill for breast cancer treatment, Pfizer and Arvinas' experimental drug ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...

and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...